Altogether, these studies suggest that chemotherapy-based multi-drug treatment may favor a specific resistance profile that may include additional mechanisms of resistance (transcriptomic, epigenetic, tumor-microenvironment-derived factors) rather than genomic-driven resistance to the anti-EGFR component of the regimen. This evidence concerns the gene EGFR and neoplasm.